Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Ame...
October 02 2017 - 4:05PM
Nightstar Therapeutics plc (“Nightstar” or the “Company”)
(NASDAQ:NITE), a clinical-stage gene therapy company developing
treatments for rare inherited retinal diseases, today announced the
closing of its previously announced initial public offering in the
United States of 6,164,000 American Depositary Shares (“ADSs”)
representing 6,164,000 ordinary shares, at an initial public
offering price of $14.00, which includes an additional 804,000 ADSs
issued upon the exercise in full by the underwriters of their
option to purchase additional ADSs. Aggregate net proceeds to
the Company, after underwriting discounts and commissions and
estimated offering expenses payable by the Company, will be
approximately $76.9 million. All of the ADSs were offered by
Nightstar.
Jefferies LLC, Leerink Partners LLC and BMO
Capital Markets Corp. acted as joint book-running managers for the
offering. Wedbush Securities Inc. and Chardan acted as
co-managers.
The offering was made only by means of a
prospectus. A copy of the prospectus relating to the offering
was filed with the U.S. Securities and Exchange Commission and may
be obtained from Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, or by telephone at (877) 547-6340, or by email at
Prospectus_Department@Jefferies.com; Leerink Partners LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6132, or
by email at Syndicate@Leerink.com; or BMO Capital Markets Corp.,
Attention: Equity Syndicate Department, 3 Times Square, New York,
NY 10036, or by telephone at (800) 414-3627, or by email at
bmoprospectus@bmo.com.
A registration statement relating to these
securities has been filed with, and declared effective by, the U.S.
Securities and Exchange Commission. This press release does
not constitute an offer to sell or the solicitation of an offer to
buy securities, and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of that jurisdiction.
About Nightstar
Nightstar is a leading clinical-stage gene
therapy company focused on developing and commercializing novel
one-time treatments for patients suffering from rare inherited
retinal diseases including choroideremia, X-linked retinitis
pigmentosa and Best vitelliform macular dystrophy.
Contact:
Senthil Sundaram, Chief Financial
Officerinvestors@nightstartx.com
Alicia Davis, THRUST IR910-620-3302alicia@thrustir.com
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Sep 2023 to Sep 2024